LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Puma Biotechnology Inc

Suletud

SektorTervishoid

4.62 3.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.39

Max

4.62

Põhinäitajad

By Trading Economics

Sissetulek

2.9M

5.9M

Müük

6.4M

52M

P/E

Sektori keskmine

4.606

35.664

Kasumimarginaal

11.166

Töötajad

172

EBITDA

6.8M

11M

Soovitused

By TipRanks

Soovitused

Müü

12 kuu keskmine prognoos

-32.89% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

72M

230M

Eelmine avamishind

1.03

Eelmine sulgemishind

4.62

Uudiste sentiment

By Acuity

50%

50%

183 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. sept 2025, 22:39 UTC

Omandamised, ülevõtmised, äriostud

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15. sept 2025, 16:43 UTC

Suurimad hinnamuutused turgudel

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15. sept 2025, 16:42 UTC

Suurimad hinnamuutused turgudel

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15. sept 2025, 16:35 UTC

Suurimad hinnamuutused turgudel

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15. sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15. sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15. sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Expects Commercial Launch in 2029

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL to Have Right to Exercise Option Based on Phase 3 Data

15. sept 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15. sept 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15. sept 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15. sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15. sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15. sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15. sept 2025, 17:50 UTC

Omandamised, ülevõtmised, äriostud

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15. sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15. sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15. sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-32.89% langus

12 kuu keskmine prognoos

Keskmine 3 USD  -32.89%

Kõrge 4 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

0

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

183 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat